Hostname: page-component-7c8c6479df-7qhmt Total loading time: 0 Render date: 2024-03-28T18:23:39.423Z Has data issue: false hasContentIssue false

Comparison of 3 Severity Criteria for Clostridium difficile Infection

Published online by Cambridge University Press:  10 May 2016

Angela Gomez-Simmonds*
Affiliation:
Division of Infectious Diseases, Columbia University Medical Center, New York, New York
Christine J. Kubin
Affiliation:
Department of Pharmacy, Division of Infectious Diseases, New York-Presbyterian Hospital and Columbia University Medical Center, New York, New York
E. Yoko Furuya
Affiliation:
Division of Infectious Diseases, Columbia University Medical Center, New York, New York
*
630 West 168th Street, Box 82, New York, NY 10032 (ag2845@columbia.edu)

Abstract

Effective severity criteria are needed to guide management of Clostridium difficile infection (CDI). In this retrospective study, outcomes were compared between patients with mild-moderate versus severe CDI according to 3 different severity criteria: those included in the 2010 Society for Healthcare Epidemiology of America/Infectious Diseases Society of America guidelines, those from a recent clinical trial, and our hospital-specific guidelines.

Type
Concise Communication
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Kelly, CP, Pothoulakis, C, LaMont, JT. Clostridium difficile colitis. N Engl ] Med 1994;330:257262.Google Scholar
2. McDonald, LC, Killgore, GE, Thompson, A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile . N Eng J Med 2005;353:24332441.Google Scholar
3. Warny, M, Pepin, J, Fang, A, et al. Increased toxins A and B production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:10791084.Google Scholar
4. Musher, DM, Aslam, S, Logan, N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:15861590.Google Scholar
5. Pepin, J, Alary, ME, Valiquette, L et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40;15911597.Google Scholar
6. Belmares, J, Gerding, DN, Parada, JP, et al. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect 2007;55:495501.Google Scholar
7. Zar, FA, Bakkanagari, SR, Moorthi, KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302307.Google Scholar
8. Cohen, SH, Gerding, DN, Johnson, S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31;431455.Google Scholar
9. Guidelines for the management of Clostridium difficile-associated disease (CDAD) in adult patients. Joint Subcommittee on Anti-Infective Use website, http://www.id.hs.columbia.edu/documents/Clinical%20References/Clostridium_Difficile_Guidelines_11-10-09.pdf. Published 2007. Accessed March 11, 2010.Google Scholar
10. Bloomfield, MG, Sherwin, JC, Gkrania-Klotsas, E. Risk factors for mortality in Clostridium difficile infection in the general hospital population: a systematic review. J Hosp Infect 2012;82:112.Google Scholar